Fennec Pharmaceuticals Inc reports results for the quarter ended in March - Earnings Summary

Fennec Pharmaceuticals

12/05/2022 12:32

* Fennec Pharmaceuticals Inc  FENC.OQ  reported a quarterly
adjusted loss of 14 cents​​ per share for the quarter ended in
March. The mean expectation of two analysts for the quarter was
for a loss of 14 cents per share.
    * Reported revenue was zero​;  analysts expected zero. 
    * Fennec Pharmaceuticals Inc's reported EPS for the quarter
was a
loss of 14 cents​.
    * The mean earnings estimate of analysts had fallen by
about 3.7%
in the last three months.​ 
    * In the last 30 days there have been no negative revisions
of
earnings estimates 
    * Fennec Pharmaceuticals Inc shares had fallen by 7.7% this
quarter and gained 17.5% so far this year.
    * The company reported a quarterly loss of $3.7 million.
    * Wall Street's median 12-month price target for Fennec
Pharmaceuticals Inc is $10.00 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 3 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell." 

This summary was machine generated May 12 at 11:32 a.m.  ​All
figures in US dollars unless otherwise stated